Predictors of mortality by an artificial intelligence enhanced electrocardiogram model for cardiac amyloidosis.

Autor: Amadio JM; Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA., Grogan M; Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA., Muchtar E; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA., Lopez-Jimenez F; Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA., Attia ZI; Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA., AbouEzzeddine O; Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA., Lin G; Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA., Dasari S; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA., Kapa S; Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA., Borgeson DD; Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA., Friedman PA; Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA., Gertz MA; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA., Murphree DH Jr; Department of Artificial Intelligence and Informatics, Mayo Clinic, Rochester, Minnesota, USA., Dispenzieri A; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Jazyk: angličtina
Zdroj: ESC heart failure [ESC Heart Fail] 2024 Aug 31. Date of Electronic Publication: 2024 Aug 31.
DOI: 10.1002/ehf2.15061
Abstrakt: Aims: We aim to determine if our previously validated, diagnostic artificial intelligence (AI) electrocardiogram (ECG) model is prognostic for survival among patients with cardiac amyloidosis (CA).
Methods: A total of 2533 patients with CA (1834 with light chain amyloidosis (AL), 530 with wild-type transthyretin amyloid protein (ATTRwt) and 169 with hereditary transthyretin amyloid (ATTRv)] were included. An amyloid AI ECG (A2E) score was calculated for each patient reflecting the likelihood of CA. CA stage was calculated using the European modification of the Mayo 2004 criteria for AL and Mayo stage for transthyretin amyloid (ATTR). Risk of death was modelled using Cox proportional hazards, and Kaplan-Meier was used to estimate survival.
Results: Median age of the cohort was 67 [inter-quartile ratio (IQR) 59, 74], and 71.6% were male. The median overall survival for the cohort was 35.6 months [95% confidence interval (CI) 32.3, 39.5]. For AL, ATTRwt and ATTRv, respectively, median survival was 22.9 (95% CI 19.2, 28.2), 47.2 (95% CI 43.4, 52.3) and 61.4 (95% CI 48.7, 75.9) months. On univariate analysis, an increasing A2E score was associated with more than a two-fold risk of all-cause death. On multivariable analysis, the A2E score retained its importance with a risk ratio of 2.0 (95% CI 1.58, 2.55) in the AL group and 2.7 (95% CI 1.81, 4.24) in the ATTR group.
Conclusions: Among patients with AL and ATTR amyloidosis, the A2E model helps to stratify risk of CA and adds another dimension of prognostication.
(© 2024 The Author(s). ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)
Databáze: MEDLINE
Externí odkaz: